Toggle light / dark theme

About 15 years ago, Stanford Medicine neuro-oncologist Michelle Monje, MD, PhD, began to suspect that the brain tumors she studied were doing something strange. Cancer cells sometimes copycat their healthy counterparts, so Monje and her team weren’t surprised to uncover simple parallels between healthy and malignant brain cells. The cancer’s biological “borrowing” was similar to a symphony-goer who whistles the theme from a concerto on the bus ride home.

But the team’s data hinted that these brain tumors were orchestrating something much more complex. Instead of just humming the themes of healthy brain biology, the research suggested the tumors could round up many important cell-signaling instruments — the microscopic equivalents of, say, violins, cellos, flutes and trombones — and use them to play a score of its own.

In physiologic terms, Monje’s team gradually demonstrated, certain cancer cells form working electrical connections with nearby nerves. The tumors wire themselves neatly into the brain’s electrical apparatus, then use healthy nerves’ signals for their own purposes — to drive malignant growth. These cancers also hijack the machinery of learning to strengthen connections with the healthy brain and further enhance their ability to multiply.

Gutierrez and Tyler investigate the limits of replicative lifespan in yeast. The authors show that nucleolar expansion during aging is a mortality timer. Enlargement of nucleoli beyond a defined size alters their biophysical properties; normally excluded DNA repair protein enter, causing aberrant rDNA recombination, genome instability and death.

Researchers have developed a new, highly effective “gene switch” to deliver targeted cell therapy.

The ETH Zurich team states that this cell therapy has the potential to offer a more precise and personalized treatment for diabetes.

Diabetes is a major global health concern, classified as a metabolic disease and affecting about one in ten individuals.

Incyte will partner with Genesis Therapeutics to research, discover, and develop small molecule treatments through a collaboration that could generate at least up to $620 million for Genesis, an artificial intelligence (AI)-based drug developer.

The companies have agreed to discover and optimize at least two initial small molecule programs through Genesis’s AI platform, Genesis Exploration of Molecular Space (GEMS). GEMS is designed to generate and optimize molecules for complex targets by integrating proprietary AI methods that include language models, diffusion models, and physical machine learning (ML) simulations.

Incyte has been granted exclusive rights for potential clinical development and commercialization of the products to be developed through the collaboration.

Elad Harel is used to shining a light on the mysteries of the natural world.

Working at the cutting edge of ultrafast spectroscopy—the use of short laser pulses to analyze molecular dynamics—the Michigan State University associate professor seeks to uncover how microscopic phenomena impact large complex systems.

One promising frontier Harel has been working on is the development of new methods of microscopy that will allow researchers to observe molecular and atomic landscapes in motion rather than through static imagery. Such work has earned Harel MSU’s 2023 Innovation of the Year award, as well as MSU’s first-ever grant from the W.M. Keck Foundation.

Imagine a supervillain attacking you with his unique superpower of creating small black holes. An invisible force zips through your body at unimaginable speed. You feel no push, no heat, yet, deep inside your body, atoms momentarily shift in response to the gravitational pull of something tiny yet immensely dense — a primordial black hole (PBH).

What would this do to you? Would it cause minor, localized damage, or would it simply rip through your entire body? Physicist Robert J. Scherrer from Vanderbilt University investigated this very scenario. His study examines what happens when a tiny black hole, like the ones formed in the early universe, passes through the human body.

The question is, of course, theoretical; but it does start from a realistic scenario. Unlike regular black holes that form when massive stars collapse, primordial black holes are thought to have emerged in the first fractions of a second after the Big Bang. While “regular” black holes typically weigh millions or billions of times more than the Sun, these PBHs could be incredibly small, with masses ranging from tiny asteroids to planets.

The key breakthrough? Finding a gene small enough to fit inside a viral delivery system. Early results in lab models suggest this therapy could be a game-changer, but further research is needed before it reaches clinical trials.

The Urgent Need for Better Arrhythmia Treatments

Cardiac arrhythmias affect millions worldwide and contribute to one in five deaths in the Netherlands. Current treatment options range from lifelong medication to invasive surgeries. However, new research from Amsterdam UMC and Johns Hopkins University, published today (February 20) in the European Heart Journal, marks a significant step toward a potential one-time gene therapy that could enhance heart function and prevent arrhythmias.

Researchers, including those from the University of Tokyo, developed Deep Nanometry, an analytical technique combining advanced optical equipment with a noise removal algorithm based on unsupervised deep learning.

Deep Nanometry can analyze nanoparticles in medical samples at high speed, making it possible to accurately detect even trace amounts of rare particles. This has proven its potential for detecting indicating early signs of colon cancer, and it is hoped that it can be applied to other medical and industrial fields.

The body is full of smaller than cells. These include extracellular vesicles (EVs), which can be useful in early disease detection and also in drug delivery.

Imagine being able to speed up evolution – hypothetically – to learn which genes might have a harmful or beneficial effect on human health. Imagine, further, being able to rapidly generate new genetic sequences that could help cure disease or solve environmental challenges.

Now, scientists have developed a generative AI tool that can predict the form and function of proteins coded in the DNA of all domains of life, identify molecules that could be useful for bioengineering and medicine, and allow labs to run dozens of other standard experiments with a virtual query – in minutes or hours instead of years (or millennia).


Trained on a dataset that includes all known living species – and a few extinct ones – Evo 2 can predict the form and function of proteins in the DNA of all domains of life.